Evotec has received a $2.9 million grant from the Gates Foundation to continue using human stem cell-based methods to identify potential fetal development risks posed by drug candidates. The funding extends a project initiated in 2023 for another three years, maintaining access to the technology for researchers working on global health programs.
The platform combines human induced pluripotent stem cell models with industrial-scale screening to model aspects of human development and identify compounds that may pose developmental risks. During the initial three-year collaboration, researchers screened more than 5,000 compounds across nine grantee programs.
Evotec said the approach is designed to help researchers assess safety liabilities earlier in discovery and decide which candidates to advance into clinical testing. Its development and validation are described in a recent bioRxiv preprint.
Chief Scientific Officer Joanna Holbrook said investigating potential effects on prenatal development through human cell behavior can inform candidate selection and reduce the risk of costly, time-consuming changes later in development. She said the continued funding will extend access to the technology for global health research.
The in vitro platform uses automation and high-content imaging to generate developmental safety data at scale. It forms part of Evotec's broader New Approach Methodologies portfolio, which the company said could reduce reliance on animal testing and improve research efficiency.
That portfolio includes more than 25 stem cell-derived cellular models, three-dimensional organoid systems, AI-supported disease modeling and screening platforms for efficacy and safety assessment. Evotec also combines machine learning, high-throughput experimentation, imaging and genome-scale molecular data to predict toxicity across organs and support decisions throughout drug discovery.